EGFR-Mutant Transformed Small Cell Lung Cancer Harbors Intratumoral Heterogeneity Targetable with MEK Inhibitor Combination Therapy

Investigators demonstrated that EGFR-mutant SCLC is composed of mixed cell states with distinct therapeutic vulnerabilities and offer a therapeutic strategy to target tumor heterogeneity in highly plastic and treatment-resistant malignancies.